Multiple Myeloma Clinical Trial
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Summary
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
Eligibility Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Participated in a previous elotuzumab protocol (including, but not limited to HuLuc63-1703, CA204007, CA204009, or CA204011) and is deemed by the investigator to be deriving benefit from elotuzumab and/or other study drugs as defined by the previous protocol
Receiving elotuzumab and/or other study drugs at the time of signature of informed consent
Males and Females, ages 18 and older
Exclusion Criteria:
All participants previously discontinued from an elotuzumab study for any reason
Participants not receiving clinical benefit from previous study therapy
Participants who are not medically well enough to receive study therapy as determined by the investigator
Other protocol defined inclusion/exclusion criteria could apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 41 Locations for this study
Tucson Arizona, 85715, United States
Bakersfield California, 93309, United States
Fountain Valley California, 92708, United States
West Hollywood California, 90069, United States
Denver Colorado, 80218, United States
Jacksonville Florida, 32256, United States
Saint Petersburg Florida, 33705, United States
Atlanta Georgia, 30322, United States
Chicago Illinois, 60637, United States
Indianapolis Indiana, 46260, United States
Boston Massachusetts, 02215, United States
Saint Louis Missouri, 63110, United States
New York New York, 10029, United States
Bethlehem Pennsylvania, 18015, United States
Dallas Texas, 75231, United States
Heidelberg Victoria, 3084, Australia
Antwerpen , 2060, Belgium
Edmonton Alberta, T6G 1, Canada
Toronto Ontario, M5G 2, Canada
Halifax , B3H 2, Canada
Athens , 11528, Greece
Budapest , 1097, Hungary
Ancona , 60126, Italy
Firenze , 50134, Italy
Genova , 16132, Italy
Torino , 10126, Italy
Aomori-shi Aomori, 03085, Japan
Shibukawa-shi Gunma, 37702, Japan
Osaka-shi Osaka, 53000, Japan
Koto-ku Tokyo, 135-8, Japan
Chiba , 260-8, Japan
Kasama-shi , 30917, Japan
Chorzow , 41-50, Poland
Warszawa , 02-10, Poland
Warszawa , 02-77, Poland
Bucuresti , 03017, Romania
Iasi , 70048, Romania
Salamanca , 37007, Spain
Toledo , 45004, Spain
Cebeci Ankara , 06620, Turkey
London , EC1A , United Kingdom
How clear is this clinincal trial information?